The US Food and Drug Administration (FDA) previously issued guidance for medical professionals that all products distributed by the New England Compounding Center (NECC) should be retained, secured, and withheld from use. 

Based on new information from the ongoing investigation, the FDA advises follow-up with patients who received an injectable product, including an ophthalmic drug that is injectable or used in conjunction with eye surgery or a cardioplegic solution bought from or produced by NECC after May 21, 2012.

The FDA does not urge follow-up for lower-risk NECC products, such as topicals (eg, lotions, creams, eyedrops not used in conjunction with surgery) and suppositories.